Kornimate/medical-research-clean huggingface dataset:
stem cell transplantation for fanconi anemia

Conditions: Fanconi Anemia

Summary: the purpose of this study is to determine whether thymic shielding during total body irradiation can be given and whether it will reduce the risk of infections in fanconi anemia patients undergoing alternate donor (not a matched sibling) stem cell transplants.

all subjects will be given the same treatment regimen of total body irradiation (tbi), fludarabine, cyclophosphamide, and anti-thymocyte globulin (atg), followed by an alternate donor stem cell transplant. since this treatment regimen has been given before, without thymic shielding, we will compare the outcomes of these patients with the historical data from subjects who did not receive thymic shielding.

Eligibility criteria:
inclusion criteria: * patients must be less than (\<) 18 years of age with a diagnosis of fanconi anemia. * patients must have an hla-a, b, drb1 identical unrelated donor or less than or equal to (≤)1 antigen mismatched related (non-hla-matched sibling) or \<1 antigen mismatched unrelated ucb donor. patients and donors will be typed for hla-a and b using serological or molecular techniques and for drb1 using high resolution molecular typing. * patients with fa must have aplastic anemia (aa), myelodysplastic syndrome without excess blasts, or high risk genotype as defined below. * aplastic anemia is defined as having at least one of the following when not receiving growth factors or transfusions * platelet count \<20 x 10\^9/l * anc \<5 x 10\^8/l * hgb \<8 g/dl * myelodysplastic syndrome with multilineage dysplasia with or without chromosomal anomalies * high risk genotype (e.g. ivs-4 or exon 14 fancc mutations, or brca1 or 2 mutations) * adequate major organ function including * cardiac: ejection fraction greater than (\>)45% * hepatic: bilirubin, ast/alt, alp \<2 x normal * karnofsky performance status \>70% or lansky performance status \>50% * women of child-bearing age must be using adequate birth control and have a negative pregnancy test exclusion criteria: * available hla-genotypically identical related donor * history of gram negative sepsis or systemic fungal infection (proven or suspected based on radiographic studies) * refractory anemia with excess blasts, or leukemia * active central nervous system (cns) leukemia at time of hematopoietic cell transplant (hct) * history of squamous cell carcinoma of the head/neck/cervix within 2 years of hct * pregnant or lactating female * prior radiation therapy preventing use of total body irradiation (tbi) 450 centigray (cgy)

Keywords: stem cell transplant thymic shielding total body irradiation chemotherapy
intervention study on digital health management

Conditions: Hypertension; Hyperlipidemia

Summary: the aim of this study is to construct a digital precision intervention system for cardiometabolism disorders based on the characteristics of the chinese population, focusing on the core components of metabolic syndrome such as hypertension, hyperglycemia, and obesity. through dynamic monitoring of wearable devices, the individualized risk factors (including genetic predisposition, lifestyle, and psychological factors) of metabolic disorders were systematically analyzed, and dynamic intervention strategies were formulated accordingly. the closed-loop management of "monitor-feedback-optimization" based on the digital platform will provide patients with one-stop metabolic risk assessment and panoramic health management plan, realizing a paradigm shift from "generalized intervention" to "precise regulation". by reducing the abnormal fluctuations of key metabolic indicators such as blood pressure, blood glucose, and blood lipids, the risk of cardiovascular events will eventually be reduced, the long-term quality of life of patients will be improved, and a practical path of "digital therapy" can be promoted for the prevention and control of chronic diseases in china


Eligibility criteria:
inclusion criteria:1. age 18-65 years old; 2. meet one of the following three conditions: 1. diastolic hypertension (systolic blood pressure \< 140 mmhg and diastolic blood pressure ≥90mmhg) 2. glycosylated hemoglobin (6.0-6.5) 3. obesity (bmi≥28kg/m²) 4. mild hyperlipemia: total cholesterol (tc) ≥5.2 mmol/l and \< 6.2 mmol/l, or low-density lipoprotein cholesterol (ldl-c) ≥3.4 mmol/l and \< 4.1 mmol/l 3. antihypertensive or lipid-lowering medications have not been started 4. use a smartphone and volunteer exclusion criteria: 1. complicated with chronic liver and kidney disease, coronary heart disease, heart failure and severe valvular disease 2. previous cardiovascular and cerebrovascular events 3. diastolic blood pressure ≥99mmhg 4. glycated hemoglobin ≥6.5 5. other life expectancy such as cancer is less than 5 years 6. participate in other clinical trials

Keywords: cardiometabolic abnormalities digital interventions
echo doppler (ed )score and d-dimer (dd) level in the evaluation of vte recurrence after anticoagulant treatment cessation

Conditions: Previous Vka Treatment; Previous Proximal VTE

Summary: the purpose of this trial is to perform a prospective multicentric study to determine predictive ed score and d-dimer level in the evaluation of the thromboembolic event recurrence after anticoagulant treatment cessation. the patients are included in the study from the anticoagulant treatment cessation. an ed score and a blood sample are performed at this time and one month later. then, the patients are followed up by phone for 2 years.

ddimer levels are centralized in university hospital of grenoble at the end of the study

Eligibility criteria:
inclusion criteria: * \> 18 and \<80 years old * first or second treated proximal vte event (+/- pulmonary embolism) * signed informed consent exclusion criteria: * active cancer or currently treated * previous vte\>2 * long term anticoagulant treatment for vte diseases * long term anticoagulant treatment for other diseases * pregnancy, parturient or breast feeding * person deprived of freedom by judicial or administrative decision * consent unsigned

Keywords: vte vka treatment vka treatment cessation
use of radiofrequency ablation to eliminate continuous atrial fibrillation in patients undergoing mitral valve surgery

Conditions: Atrial Fibrillation; Radiofrequency Catheter Ablation

Summary: the aim of this prospective randomized clinical trial was to evaluate the early and late outcome following left atrial radiofrequency ablation during mv surgery for the treatment of continuous atrial fibrillation and to assess the functional effects of restoration of sinus rhythm.

atrial fibrillation (af) is a frequent and important contributor to symptoms and morbidity in patients with mitral valve (mv) disease.radiofrequency ablation (rfa) of the left atrium (la) during open- heart surgery has emerged as a novel surgical modality for the treatment of af. although rfa therapy of the la is being increasingly offered to patients with chronic af undergoing mv surgery, its efficacy has not been tested in the context of an adequately powered randomized study. the aim of this prospective randomized clinical trial was to evaluate the early and late outcome following left atrial rfa during mv surgery for the treatment of continuous af and to assess the functional effects of restoration of sr. patients were randomized to undergo mv surgery or mv surgery plus rfa of the la. additional cardiac procedures were performed as required. the primary outcome endpoint was the presence of sr at 12 months. secondary endpoints included patient functional status and exercise capacity, la contractility, and la and left ventricular (lv) dimension and function and plasma levels of b-type natriuretic peptide (bnp).

Eligibility criteria:
inclusion criteria: * patients requiring mv surgery with at least 6 month history of atrial fibrillation exclusion criteria: * patients with sick sinus syndrome * hyperthyroidism * permanent pacemaker * previous cardiac surgery

Keywords: radiofrequency catheter ablation atrial fibrillation randomized trial
gamified infection control education for nursing students: effects on self-efficacy, motivation, and learning outcomes

Conditions: Students, Nursing

Summary: infection control is a critical component of nursing education, ensuring the safety of patients and healthcare workers. gamification, which integrates game-based principles into educational activities, has emerged as a promising approach to improve student engagement, motivation, and learning outcomes in healthcare education. this study aimed to evaluate the impact of a gamified infection control education program on cognitive achievement, academic self-efficacy, and learning motivation among first-year nursing students. the study employed a randomized controlled trial design involving 60 first-year nursing students from a private university in turkey. participants were randomly assigned to an intervention group (n=30) or a control group (n=30). the intervention group participated in a four-week gamified infection control program featuring physical games, case studies, and escape rooms. the control group received traditional lecture-based instruction. data were collected using validated instruments, including the infection control cognitive achievement measurement questions form, the academic nurse self-efficacy scale (anses), and the learning motivation scale in higher education (emapre-u). statistical analyses included t-tests, mann-whitney u tests, and regression analyses.


Eligibility criteria:
inclusion criteria: * first-year nursing students enrolled in a nursing program * students who have not previously completed formal infection control training * students who are willing to participate in the study and provide informed consent exclusion criteria: * students with prior knowledge or certification in infection control practices * students who are unable to attend the full four-week program due to scheduling conflicts * students with any medical or psychological condition that would prevent full participation in study activities

Keywords: gamification infection control nursing student academic success self efficacy
effects of vitamin d status on the outcome of ivf - embryo transfer

Conditions: Infertility, Female

Summary: at present, there is no agreement on the effect of vitamin d level in serum and follicular fluid on the outcome of ivf-et pregnancy. most of these studies were based on the research of total 25 (oh) d, which have ignored that the biological activity of vitamin d molecule is not total 25 (oh) d, but free vitamin d or vitamin d bioavailable, and have flaws in methodology. this project intends to make a prospective cohort study with large sample, based on a complete methodology of total vitamin d and free vitamin d to measure maternal vitamin d levels in blood,to systematically study the effect of maternal vitamin d status on ivf - et pregnancy outcome. this study is also the first to study the relationship between maternal vitamin d status and the outcome of ivf-et pregnancy using a complete methodology.


Eligibility criteria:
inclusion criteria: * female with only fallopian tube factor or male factor infertility,first ivf/icsi cycle,18 years old≤age≤35 years old,take a long protocol or super-long protocol,18≤bmi≤25, menstrual regularity(periodic change \< 7 days) exclusion criteria: * hyperprolactinemia, thyroid dysfunction, uterine malformation ( inadequacy mediastinal uterus ≥1.0cm, unicornate uterus, double uterus, t angle of uterus, etc.), uterus adhesion, untreated hydrosalpinx , hysteromyoma（ hysteromyoma≥2.0 cm, and/or uterine fibroids located within the endometrium≤1cm), endometriosis, diabetes, hypertension, adrenal cortex hyperplasia, cushing's syndrome, a pituitary amenorrhea
changes in weight, body composition and cardiac risk after discontinuing abacavir treatment in hiv-infected individuals

Conditions: Hiv; HIV Infections; HIV Cardiomyopathy; Weight Change, Body; HIV Lipodystrophy; Cardiovascular Diseases

Summary: randomized controlled parallel open-label study in people living with hiv and at least 6 month of treatment with dolutegravir/abacavir/lamivudine prior to inclusion. participants (n=95) are randomized to continue 3 drug-regimen dolutegravir/abacavir/lamivudine (control) or switch to two-drug regimen with dolutegravir/lamivudine (intervention). follow-up is 48 weeks. data is collected at baseline and week 48. primary outcome is changes in weight from baseline of more than 2 kg. secondary outcomes are changes in cardiac risk, composition and calcification of the heart tissue, and changes in body composition and metabolism, inflammation and coagulation. a mri substudy is applied to focus on the cardiac adverse effects of abacavir.

in the mri sub study 40 patients from the main study (20 from each group) are included. a cardiac mri are performed at baseline and week 48 to evaluate cardiac effects of abacavir.

Eligibility criteria:
inclusion criteria: * ≥ 18 years old * diagnosed hiv * at least 6 months of ongoing treatment with dolutegravir/ abacavir/lamivudine * plasma viral load (hiv-rna) \< 50 copies/ml at inclusion for women of childbearing potential: * negative pregnancy test * willingness to use contraceptive (consistent with local regulations) during study period exclusion criteria: * pre-existing viral resistance mutations to lamivudine or to dolutegravir * presence of hepatitis b antigen (hbsag) or hepatitis b virus dna (hbv dna) * cancer within past 5 years * diabetes, cardiovascular disease or other chronic illness considered stable as assessed by the treating physician for women of childbearing potential: * pregnancy * breastfeeding

Keywords: hiv weight changes antiretroviral therapy cardiovascular disease antiretroviral therapy side effects antiretroviral two-drug regimen hiv metabolism hiv diabetes
the influence of different at-home exercise strategies on 24h glycemic control

Conditions: Metabolic Disturbance

Summary: this study will determine how different at-home exercise strategies influence 24hr glycemic control in women with metabolic dysfunction.

elevations in blood glucose concentration increase risk for cardiometabolic diseases including type 2 diabetes and cardiovascular diseases. exercise can improve glycemic control, but there is limited research comparing the effectiveness of different exercise strategies in women. the aim of this study is to examine, under free-living conditions, how performing either walking and bodyweight interval exercise after dinner influences glycemic control in women with or at risk for type 2 diabetes. glycemic control will be measured with continuous glucose monitors.

Eligibility criteria:
inclusion criteria: * females * no cancer history * ≥50 years old * have metabolic dysfunction (defined as self-reported diagnosis of pre-diabetes, type 2 diabetes, or at least moderate canadian diabetes risk (canrisk) score) * owns a smartphone with bluetooth capability with apple or android operating system * deemed safe to exercise as per the csep get active questionnaire * enrolled in nct05454943 exclusion criteria: * type 1 diabetes * taking exogenous insulin, sulfonylureas, or glp-1 receptor agonists * self-reported history of an eating disorder * bmi \<18.5 kg/m * working night or rotating shifts * eating window \<12 hours or consistently eating less than 3 meals/day in the past 3 months * major dietary changes within the past 3 months (i.e. calorie counting, ketogenic diet)

Keywords: women glycemic control exercise
fast food feeding in youth

Conditions: Obesity

Summary: the primary aim of the proposed pilot study is to assess the effects of fast food meals, varying in serving size and rate of delivery, on energy (calorie) intake in adolescents.

using a three-period crossover design, the investigators will evaluate three acute feeding conditions. * under condition a, the total amount of food in a large fast food meal will be delivered on a single tray at time 0 (start of meal). * under condition b, the same fast food meal will be equally divided among 4 separate portions, with all portions delivered at time 0. * under condition c, the meal again will be equally divided among 4 separate portions, but the portions will be delivered at 15-minute time intervals (time 0, 15 minutes, 30 minutes, 45 minutes).

Eligibility criteria:
inclusion criteria: * body mass index (bmi) between the 85th and 98th percentiles for sex and age * consumption of fast food at least one time per week * willingness to eat the foods specified in the research methods * parent/guardian willing and able to cooperate * access to a working telephone exclusion criteria: * major medical illness (eg, diabetes; heart, renal, or liver disease; cancer; endocrinopathy) * taking any prescription medication that may affect food intake * current smoking (i.e., any tobacco in the last month) * previous diagnosis of an eating disorder
dexamethasone for the prevention of recurrent laryngeal nerve palsy

Conditions: Benign Neoplasm of Thyroid Gland; Malignant Neoplasm of Thyroid

Summary: recurrent laryngeal nerve dysfunction and hypoparathyroidism are well-recognized important complications of thyroid surgery. the duration of convalescence, after non complicated thyroid operation, may depend on several factors of which pain and fatigue are the most important. nausea and vomiting occur mainly on the day of operation. glucocorticoids are well known for their analgesic, anti-inflammatory, immune modulating and antiemetic effects. the investigators therefore undertook the present study to investigate whether preoperative dexamethasone could improve surgical outcome in patients undergoing thyroid surgery.


Eligibility criteria:
inclusion criteria: * patients undergoing thyroid surgery exclusion criteria: * asa physical class iii or iv * age \> 75 years * pregnancy
evaluation of a bioimpedance method for determination of dry weight in dialysis patients

Conditions: Renal Insufficiency, Chronic

Summary: the purpose of this study is the evaluation of a bioimpedance method for determination of dry weight in dialysis patients. additionally normal tissue hydration in non-dialysis patients is investigated in healthy subjects and patients with chronic kidney disease in stages k/digo i-iv


Eligibility criteria:
inclusion criteria: * clinically stable on dialysis within the last three months * signed written informed consent exclusion criteria: * acute myocardial infarction or stroke within the last six months * heart failure stage nyha iv * concommitant participation in other interventional trials * psychiatric conditions that prevent subject from following the study procedures / protocol * pregnancy or lactation * limb amputation * cardiac pacemaker * joint implants * implantable pumps and other metallic implants for healthy subjects and ckd patients in stages k/digo i-iv the above mentioned criteria other than the first mentioned are applicable respectively.
symptom-based rehabilitation compared to usual care in post-covid - a randomized controlled trial

Conditions: COVID-19; Long-COVID

Summary: inpatient, multimodal rehabilitation represents one of the most important interventions in the disease management of post/long covid. different professional societies, including the german society of pneumology and the european respiratory society, recommend rehabilitation intervention to reduce the sequelae of covid-19. however, from the perspective of science and practice, there are relevant areas that have been insufficiently investigated and are essential for the treatment success of post/long covid patients: * differentiation of rehabilitation effects from natural recovery after covid-19. * lack of personalized and symptom-based treatment approaches that can address the heterogeneity of symptoms in post/long covid * lack of uniform, high-quality rehabilitation standards in post-/long-covid. therefore, post-covid patients will be recruited at several post-covid practices around germany and randomized to receive (a) a rehabilitation program or (b) usual care. the primary objective of this randomized controlled trial (rct) is to investigate whether a 3-week symptom-oriented, inpatient, multidisciplinary rehabilitation intervention, whose content focus is standardized according to cluster assignment (fatigue, cognition, soma), has a positive effect on the quality of life (primary outcome) in post-covid syndrome patients compared to a usual care group (standard outpatient care). all study participants will be provided with a continuous telemonitoring system (saniq app) throughout the study period. after the interventional phase, there will be a 3 months follow-up assessment to evaluate the maintenance effects of covid rehabilitation.


Eligibility criteria:
inclusion criteria: * post-covid syndrome according to world health organisation definition (persistent symptoms for at least 3 months after pcr-test confirmed sars-cov 2 infection) exclusion criteria: * no walking ability * not able to operate smartphone apps * rehabilitation program within the previous 6 months

Keywords: rehabilitation intervention quality of life long-covid post-covid syndrome sequelae recovery
subcutaneous tarlatamab in participants with extensive stage small cell lung cancer (dellphi-308)

Conditions: Extensive Stage Small Cell Lung Cancer

Summary: the primary objective of this study is to evaluate the safety and tolerability of subcutaneous (sc) tarlatamab.


Eligibility criteria:
inclusion criteria: * participants ≥ 18 years of age (or ≥ legal adult age within country if it is older than 18 years) at time of signing informed consent. * participants with histologically or cytologically confirmed es-sclc that progressed or recurred following at least one line of platinum-based anti-cancer therapy for sclc. note: participants with prior treatment for ls-sclc should have also received another regimen for their recurrent, es-sclc disease. * eastern cooperative oncology group (ecog) performance status (ps) of 0 or 1. * participants must have adequate organ function (cardiac, pulmonary, kidney, and liver). * participants must be able to have sc injections administered in the abdomen (and/or thigh). * participants without measurable disease or tumor tissue (fresh biopsy or archival) available may be permitted after discussion with and approval by amgen medical monitor. exclusion criteria: * participants that have received prior dll3 targeted therapy. * participants with untreated or symptomatic brain metastases or those requiring therapy with steroids. * note: participants with asymptomatic brain metastatic lesions are allowed following definitive treatment (amgen medical monitor may approve untreated, asymptomatic brain metastasis if local therapy is not required per investigator judgment). * participants with leptomeningeal disease. * participants with baseline oxygen requirement.

Keywords: small cell lung cancer